RPRX and ZBIO Related Headlines
Go Back- Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab
- Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
- Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
RPRX and ZBIO Related Press Releases
Go Back- Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
- Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
